If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine) injection
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How are patients transitioned from another basal insulin to Basaglar® (insulin glargine)?
If transitioning from another basal insulin to Basaglar, the recommended initial Basaglar dose is based on the insulin therapy that is being discontinued.
Transitioning From Another Basal Insulin to Basaglar Therapy
If transitioning patients from another basal insulin to Basaglar® (insulin glargine) 100 units/mL therapy, the recommended initial dose of Basaglar is based on the insulin therapy that is being discontinued (Transitioning From Another Basal Insulin to Basaglar Therapy).1
If transitioning from… |
To… |
Then the recommended initial dose of Basaglar… |
Example |
Lantus |
Basaglar |
is the same as the Lantus dose. |
50 units of Lantus transitions to 50 units of Basaglar |
Toujeo |
Basaglar |
is 80% of the Toujeo dose. |
50 units of Toujeo transitions to 40 units of Basaglar |
twice-daily NPH insulin |
once-daily Basaglar |
is 80% of the total daily NPH insulin dosage. |
25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 40 units of Basaglar once daily |
an intermediate- or long-acting insulin other than Lantus |
Basaglar |
may differ from the prior basal insulin dose. |
… |
Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL; Toujeo = Toujeo® (insulin glargine) 300 units/mL.
Enclosed Prescribing Information
Reference
1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: August 22, 2022